Effect of revascularization on IL-6 and TNF-α in patients with thromboangiitis obliterans

Wu,Shifeng; Sun,Xin; Wu,Wei; Shi,Dazhi; Jiang,Tao

doi:10.3892/etm.2018.5877

Effect of revascularization on IL-6 and TNF-α in patients with thromboangiitis obliterans

Authors:
- Shifeng Wu
- Xin Sun
- Wei Wu
- Dazhi Shi
- Tao Jiang
View Affiliations

Affiliations: Department of Burns and Plastic Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Neurosurgery, The First Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Intensive Care Unit, The Fourth Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Vascular Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: February 20, 2018 https://doi.org/10.3892/etm.2018.5877
Pages: 3947-3951
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the study was to investigate the effects of revascularization in treating patients with thromboangiitis obliterans (TAO), to analyze the prognosis of TAO. The treatment group comprised 32 patients with TAO of lower limbs who were selected between March 2012 and March 2017. Patients in the treatment group were treated with revascularization (vascular bypass surgery, catheter-directed thrombolysis and angioplasty, endovascular angioplasty + stening, thromboectomy and/or endarterectomy) + Western medicine. Another 33 patients with TAO who were treated with Western medicine alone comprised the control group. Treatment outcomes were compared between the groups. Serum levels of interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) were also detected and compared between the groups. Multivariate analysis was performed to identify the factors related to prognosis. Compared with control group, treatment outcomes were significantly better in the treatment group (P<0.05). After treatment, the serum levels of IL-6, IL-8 and TNF-α significantly decreased in both groups, and the decrease in the treatment group was more significant (P<0.01). Multivariate analysis revealed that vascular bypass surgery and preoperative ischemic degree are associated with treatment effect. Our results show that revascularization treatment of TAO is conducive to clinical symptoms and dysfunction of inflammatory cytokines, and the type of surgery and surgical timing significantly affect treatment outcomes.

View Figures

View References

1	Mills JL Sr: Buerger's disease in the 21st century: Diagnosis, clinical features, and therapy. Semin Vasc Surg. 16:179–189. 2003. View Article : Google Scholar : PubMed/NCBI
2	Kocak B and Ustun ED: Vasa nervorum as the source of corkscrew collaterals in thromboangiitis obliterans (Buerger's Disease). Eur J Vasc Endovasc Surg. 52:5082016. View Article : Google Scholar : PubMed/NCBI
3	Klein-Weigel PF and Richter JG: Thromboangiitis obliterans (Buerger's disease). Vasa. 43:337–346. 2014. View Article : Google Scholar : PubMed/NCBI
4	Rivera-Chavarría IJ and Brenes-Gutiérrez JD: Thromboangiitis obliterans (Buerger's disease). Ann Med Surg (Lond). 7:79–82. 2016. View Article : Google Scholar : PubMed/NCBI
5	Highlander P, Southerland CC, VonHerbulis E and Gonzalez A: Buerger disease (thromboangiitis obliterans): A clinical diagnosis. Adv Skin Wound Care. 24:15–17. 2011. View Article : Google Scholar : PubMed/NCBI
6	Szuba A and Cooke JP: Thromboangiitis obliterans. An update on Buerger's disease. West J Med. 168:255–260. 1998.PubMed/NCBI
7	Rimar D, Rozenbaum M, Slobodin G, Boulman N, KaLy L and Rosner I: Thromboangiitis obliterans overlapping with atherosclerotic occlusive arterial disease: Small merenteric artery involvement by thromboangiitis obliterans. Harefuah. 155:41–44, 67,66. 2016.(In Hebrew). PubMed/NCBI
8	Abyshov NS, Abdullayev AG, Zakirdzhaev ED, Guliyev RA, Akhmedov MB, Tagizade GT, Zeynalova GM and Mamedova LD: The results of combined surgical treatment of thromboangiitis obliterans and critical lower limb ischemia using prolonged epidural analgesia and autohemotherapy with ozone. Khirurgiia (Mosk). 9:45–50. 2016.(In Russian).
9	Aszalos C, Dongó E, Farkas Z, Kollár A, Magyar P, Várallyay G, Bereczki D and Vastagh I: Cerebral manifestations of thromboangiitis obliterans. Case report. Orv Hetil. 157:1207–1211. 2016.(In Hungarian). View Article : Google Scholar
10	Kawarada O, Sakamoto S, Harada K, Ishihara M, Yasuda S and Ogawa H: Endovascular recanalization of failed distal bypass in Buerger's disease. Cardiovasc Interv Ther. 29:266–269. 2014. View Article : Google Scholar : PubMed/NCBI
11	Zeng R, Ye W, Li YJ, Shao J, Zheng YH and Liu CW: Revascularization for lower limbs thromboangiitis obliterans-early and mid-term outcome report. Zhonghua Wai Ke Za Zhi. 51:719–722. 2013.(In Chinese). PubMed/NCBI
12	Shionoya S, Ban I, Nakata Y, Matsubara J, Hirai M and Kawai S: Surgical treatment of Buerger's disease. J Cardiovasc Surg (Torino). 21:77–84. 1980.PubMed/NCBI
13	Piazza G and Creager MA: Thromboangiitis obliterans. Circulation. 121:1858–1861. 2010. View Article : Google Scholar : PubMed/NCBI
14	Owlia MB and Mehrpoor G: Thromboangiitis obliterans with cryoglobulinemia. J Coll Physicians Surg Pak. 24:863–864. 2014.PubMed/NCBI
15	Modaghegh MH, Kazemzadeh GH, Ravari H, Johari HG and Barzanuni A: Buerger's disease in the northeast of Iran: Epidemiology and clinical features. Vascular. 23:519–524. 2015. View Article : Google Scholar : PubMed/NCBI
16	Sapkota P, Budhathoky P and Mathew S: Smoking and Thromboangitis Obliterans - Are they related? JNMA J Nepal Med Assoc. 52:802–805. 2014.PubMed/NCBI
17	Johnson JA and Enzenauer RJ: Inflammatory arthritis associated with thromboangiitis obliterans. J Clin Rheumatol. 9:37–40. 2003. View Article : Google Scholar : PubMed/NCBI
18	Puéchal X and Fiessinger JN: Thromboangiitis obliterans or Buerger's disease: Challenges for the rheumatologist. Rheumatology (Oxford). 46:192–199. 2007. View Article : Google Scholar : PubMed/NCBI
19	Azizi M, Boutouyrie P, Bura-Rivière A, Peyrard S, Laurent S and Fiessinger JN: Thromboangiitis obliterans and endothelial function. Eur J Clin Invest. 40:518–526. 2010. View Article : Google Scholar : PubMed/NCBI
20	Hartge MM, Kintscher U and Unger T: Endothelial dysfunction and its role in diabetic vascular disease. Endocrinol Metab Clin North Am. 35:551–560. 2006. View Article : Google Scholar : PubMed/NCBI
21	Slavov ES, Stanilova SA, Petkov DP and Dobreva ZG: Cytokine production in thromboangiitis obliterans patients: New evidence for an immune-mediated inflammatory disorder. Clin Exp Rheumatol. 23:219–226. 2005.PubMed/NCBI
22	Halacheva K, Gulubova MV, Manolova I and Petkov D: Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta Histochem. 104:177–184. 2002. View Article : Google Scholar : PubMed/NCBI
23	Huang WY, Wang J, Liu YM, Zheng QS and Li CY: Inhibitory effect of Malvidin on TNF-α-induced inflammatory response in endothelial cells. Eur J Pharmacol. 723:67–72. 2014. View Article : Google Scholar : PubMed/NCBI
24	Dellalibera-Joviliano R, Joviliano EE, Silva JS and Evora PR: Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients. Clin Exp Immunol. 170:28–35. 2012. View Article : Google Scholar : PubMed/NCBI